טוען...
Cutaneous Toxicities of Molecular Targeted Therapies
Antineoplastic targeted therapies, such as EGFR inhibitors, tyrosine kinase inhibitors and BRAF inhibitors, frequently lead to systemic and cutaneous side effects, significantly affecting patient’s quality of life. Patients with new targeted therapies have an increased risk of developing skin reacti...
שמור ב:
| הוצא לאור ב: | Maedica (Bucur) |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
EDITORIAL POINT OF VIEW
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5574072/ https://ncbi.nlm.nih.gov/pubmed/28878837 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|